We are live on ! Find out more
PVCT

Provectus Biopharmaceuticals
PVCT

Delisted

PVCT was delisted on the 13th of October, 2016.

39 hedge funds and large institutions have $6.13M invested in Provectus Biopharmaceuticals in 2015 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 9 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 3

8% more funds holding

Funds holding: 36 → 39 (+3)

1% less ownership

Funds ownership: 6.21% → 5.22% (-1%)

44% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 9

51% less capital inflows, than outflows

Capital inflows: $1.04M | Capital outflows: $2.12M

Holders
39
Holders Change
+3
Holders Change %
+8.33%
% of All Funds
1.09%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
5
Reduced
9
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

PVCT Hedge Fund Activity: Q3 2015 in Review

39 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Provectus Biopharmaceuticals (PVCT) for Q3 2015, worth a combined $6.13M — down 7.7% from $6.64M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new PVCT positions and 3 closed out — a net gain of 3 holders — while 5 added to existing stakes and 9 trimmed.

The largest buyer was Goldman Sachs, opening a new position worth an estimated $493K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $1.32M sold.

  • 39 institutional investors held Provectus Biopharmaceuticals (PVCT) as of Q3 2015, up from 36 in Q2 2015.
  • Funds reported $6.13M of Provectus Biopharmaceuticals stock for Q3 2015, down 7.7% quarter-over-quarter.
  • 6 funds opened new Provectus Biopharmaceuticals positions in Q3 2015 and 3 closed out, a net change of +3 holders.
  • The largest Provectus Biopharmaceuticals buyer in Q3 2015 was Goldman Sachs, an estimated $493K added.
  • The largest Provectus Biopharmaceuticals seller in Q3 2015 was Susquehanna International Group, an estimated $1.32M sold.

Based on aggregated 13F filings for Q3 2015.